TREATMENT OF CARDIOVASCULAR DISEASES IN PATIENTS WITH PSORIASIS

Highlights

Considering the systemic nature of psoriasis and the high prevalence of cardiovascular diseases among this cohort of patients, it is particularly important to focus on the therapy of these conditions in real clinical practice. Thus, the correct choice of pharmacological strategy and timely adjustment of the ongoing therapy play a crucial role in the course of these diseases.

Abstract

Background. Currently, psoriasis, as a chronic immune-mediated disease of a multifactorial nature, is one of the most common diseases worldwide. Given the systemic nature of this disease, the level of comorbid pathologies is high, especially those associated with cardiovascular diseases.

Aim. To assess the features of the ongoing therapy for psoriasis and CVD in real clinical practice.

Methods. The open prospective observational clinical study was conducted. 160 patients diagnosed with mild to severe generalized psoriasis vulgaris constituted the main group, 40 patients were included in the control group. All patients underwent basic clinical and laboratory tests, physical examination with an assessment of body mass index, severity of the disease according to the PASI and DLQI index, psycho-emotional state, and measurement of blood pressure using the Korotkov method. Depending on the age of the patient, the cardiovascular risk (CVR) was assessed using the SCORE2/2OP scale. The therapy used to treat patients with psoriasis and CVD was analyzed.

Results. According to the results of the study, patients with high cardiovascular risk (47%) prevail among the patients of the main group, compared with the control group (CG) (30%). There is a high incidence of arterial hypertension (AH) – 34.4% (CG – 22.5%), dyslipidemia – 40% (CG – 5%) (of which only 60% received lipid-lowering therapy), rhythm disturbances – 2% (CG – 1%), CHF – 1% (CG – 1%). Optimal antihypertensive therapy was received by 80% of patients, 20% required hospitalization in the Internal Medicine Department for additional examination and correction of CVD therapy. The use of systemic therapy was quite frequent: 21% received methotrexate, 23% – biological therapy.

Conclusion. Thus, in real clinical practice, constant assessment and prevention of CV risk, monitoring of risk factors such as weight, blood pressure, BMI, cholesterol, PASI and DLQI are necessary for a patient-specific, multidisciplinary approach to the treatment of patients with psoriasis and CVD.

1. Kubanov A.A., Bogdanova E.E. Epidemiology of psoriasis among the elderly population and volume of specialized medical care provided to patients with psoriasis in the Russian Federation in 2010–2019. Vestn Dermatol Venerol. 2020; 96: 7–18. doi:10.25208/vdv1171-2020-96-5-07-18.

2. Rendon A., Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019; 20: 1475. doi:10.3390/ijms20061475.

3. Andújar I., Esplugues J.V., García-Martínez P. Looking beyond the Skin: Pathophysiology of Cardiovascular Comorbidity in Psoriasis and the Protective Role of Biologics. Pharmaceuticals. 2022; 15: 1101. doi:10.3390/PH15091101.

4. Liu L., Cui S., Liu M., Huo X., Zhang G., Wang N. Psoriasis Increased the Risk of Adverse Cardiovascular Outcomes: A New Systematic Review and Meta-Analysis of Cohort Study. Front Cardiovasc Med. 2022; 9: 1–12 doi:10.3389/fcvm.2022.829709.

5. Gonzalez-Cantero A., Reddy A.S., Dey A.K., Gonzalez-Cantero J., Munger E., Rodante J., Sanchez-Moya A.I., Perez-Hortet C., et al. Underperformance of clinical risk scores in identifying imaging-based high cardiovascular risk in psoriasis: results from two observational cohorts. Eur J Prev Cardiol. 2022; 29: 591–598. doi:10.1093/eurjpc/zwaa033.

6. Mw D., Hajdarbegovic B.E. Drug-induced psoriasis: clinical perspectives. Psoriasis: Targets and Therapy. 2017; 7: 87–94. doi:10.2147/PTT.S126727.

7. Svechnikova E.V., Morzhanaeva M.A., Shchepkina E.V. Estimating Treatment Costs for Moderate and Severe Psoriasis With Comorbidities. Bulletin of the Medical Institute of Continuing Education. 2024; 4: 117–122. doi: 10.36107/2782-1714_2024-4-2-107-116 (In Russian)

8. Zhao S.S., Yiu Z.Z.N., Barton A., Bowes J. Association of Lipid-Lowering Drugs With Risk of Psoriasis: A Mendelian Randomization Study. JAMA Dermatol. 2023; 159: 275–280. doi:10.1001/JAMADERMATOL.2022.6051.

9. Клинические рекомендации по ведению больных псориазом. Общероссийская общественная организация «Российское общество дерматовенерологов и косметологов», https://www.rodv.ru/upload/iblock/aa2/aa20a2fc65b13df3899140167777092d.pdf (2023).

10. Rungapiromnan W., Mason K.J., Lunt M., McElhone K., Burden A.D., Rutter M.K., Warren R.B., Griffiths C.E.M., Ashcroft D.M.; BADBIR Study Group. Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. J Eur Acad Dermatol Venereol. 2020; 34: 769–778. doi:10.1111/jdv.16018.

11. Rungapiromnan W., Yiu Z.Z.N., Warren R.B., Griffiths C.E.M., Ashcroft D.M. Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. Br J Dermatol. 2017; 176: 890–901. doi:10.1111/BJD.14964.

12. Terui H., Asano Y. Biologics for Reducing Cardiovascular Risk in Psoriasis Patients. J Clin Med. 12. Epub ahead of print 1 February 2023. doi:10.3390/JCM12031162.

13. Elnabawi Y.A., Dey A.K., Goyal A., Groenendyk J.W., Chung J.H., Belur A.D., Rodante J., Harrington C.L., et al. Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovasc Res. 2019; 115: 721–728. doi:10.1093/CVR/CVZ009.

14. Schüler R., Brand A., Klebow S., Wild J., Veras F.P., Ullmann E., Roohani S., Kolbinger F., et al. Antagonization of IL-17A Attenuates Skin Inflammation and Vascular Dysfunction in Mouse Models of Psoriasis. J Invest Dermatol. 2019; 139: 638–647. doi:10.1016/J.JID.2018.09.021.

15. Ridker P.M., Everett B.M., Thuren T., MacFadyen J.G., Chang W.H., Ballantyne C., Fonseca F., Nicolau J.,et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017; 377: 1119–1131. doi: 10.1056/NEJMoa1707914.

16. Abbas A., Gregersen I., Holm S., Daissormont I., Bjerkeli V., Krohg-Sørensen K., Skagen K.R., Dahl T.B., et al. Interleukin 23 levels are increased in carotid atherosclerosis: possible role for the interleukin 23/interleukin 17 axis. Stroke. 2015; 46: 793–799. doi:10.1161/STROKEAHA.114.006516.

17. Subramanian M., Thorp E., Tabas I. Identification of a non-growth factor role for GM-CSF in advanced atherosclerosis: promotion of macrophage apoptosis and plaque necrosis through IL-23 signaling. Circ Res. 2015; 116: e13–e24 doi:10.1161/CIRCRESAHA.116.304794.

18. Madhur M.S., Funt S.A., Li L., Vinh A., Chen W., Lob H.E., Iwakura Y., Blinder Y., Rahman A., Quyyumi A.A., Harrison D.G. Role of interleukin 17 in inflammation, atherosclerosis, and vascular function in apolipoprotein e-deficient mice. Arterioscler Thromb Vasc Biol. 2011; 31: 1565–1572 doi:10.1161/ATVBAHA.111.227629.

19. Ryan C., Leonardi C.L., Krueger J.G., Kimball A.B., Strober B.E., Gordon K.B., Langley R.G., de Lemos J.A., Daoud Y., et al. Association Between Biologic Therapies for Chronic Plaque Psoriasis and Cardiovascular Events: A Meta-analysis of Randomized Controlled Trials. JAMA. 2011; 306: 864–871 doi:10.1001/JAMA.2011.1211.

20. Madhur M.S., Lob H.E., McCann L.A., Iwakura Y., Blinder Y., Guzik T.J., Harrison D.G. Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction. Hypertension. 2010; 55: 500–507 doi:10.1161/HYPERTENSIONAHA.109.145094.

21. Российское кардиологическое общество (РКО). Артериальная гипертензия у взрослых. Клинические рекомендации, 2022. 138.

22. Rossijskoe kardiologicheskoe obshhestvo (RKO). Stabil'naja ishemicheskaja bolezn' serdca. Klinicheskie rekomendacii, 2022. Available at: https://scardio.ru/content/Guidelines/Proekt_2023_SIBS.pdf (accessed 20.02.2025) (In Russian)

23. Rossijskoe kardiologicheskoe obshhestvo (RKO). Narushenija lipidnogo obmena. Klinicheskie rekomendacii, 2023. Available at: https://cardioc.ru/spetsialistam/klinicheskie-rekomendatsii/2023/2023_narusheniya_lo.pdf (accessed 20.02.2025) (In Russian)

24. SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: Estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021; 42: 2455–2467 doi:10.1093/eurheartj/ehab312.

25. Kuzmina O.A., Mironova O.Iu., Lepekhova A.A., Fomin V.V. The prevalence of hypertension among patients with psoriasis in clinical practice. Consilium Medicum. 2022; 24: 763–766 doi:10.26442/20751753.2022.10.201926. (In Russian)

26. Holmes M.V., Millwood I.Y., Kartsonaki C., Hill M.R., Bennett D.A., Boxall R., Guo Y., Xu X., et al. Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke. J Am Coll Cardiol. 2018; 71: 620 doi:10.1016/J.JACC.2017.12.006.

27. El Khoudary S.R., Shields K.J., Janssen I., Hanley C., Budoff M.J., Barinas-Mitchell E., Everson-Rose S.A., Powell L.H., Matthews K.A. Cardiovascular fat, menopause, and sex hormones in women: The SWAN cardiovascular fat ancillary study. J Clin Endocrinol Metab. 2015; 100: 3304–3312 doi:10.1210/JC.2015-2110.

28. Barbieri J.S., Beidas R.S., Gondo G.C., Fishman J., Williams N.J., Armstrong A.W., Ogdie A.R., Mehta N., Gelfand J.M. Analysis of Specialist and Patient Perspectives on Strategies to Improve Cardiovascular Disease Prevention Among Persons With Psoriatic Disease. JAMA Dermatol. 2022;158(3):252-259. doi: 10.1001/jamadermatol.2021.4467.